• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Heart Failure Study Shows Baseline Dependent Blood Pressure Changes With Dapagliflozin

by
November 8, 2026
in Health
Reading Time: 2 mins read
0
Heart Failure Study Shows Baseline Dependent Blood Pressure Changes With Dapagliflozin

Heart Failure Study Shows Baseline Dependent Blood Pressure Changes With Dapagliflozin

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patients with heart failure with reduced ejection fraction who initiated dapagliflozin therapy in routine clinical practice demonstrated a baseline-dependent blood pressure response across office, central aortic, and 24-hour ambulatory measurements, according to prospective observational findings published in BMC Cardiovascular Disorders. Following the initiation of dapagliflozin, researchers recorded modest numerical reductions in blood pressure across all evaluated modalities. Rather than producing a uniform blood pressure-lowering effect across the cohort, the extent of reduction corresponded directly to initial levels: individuals with higher baseline values experienced larger reductions, whereas patients presenting with lower starting blood pressure exhibited minimal changes.

The research sought to address ongoing clinical concerns regarding the potential for excessive blood pressure reduction in patients with heart failure with reduced ejection fraction treated with sodium–glucose cotransporter 2 inhibitors. Such concerns have persisted particularly for individuals presenting with lower baseline blood pressure, a population for whom real-world data combining office, central, and ambulatory measurements have remained limited. To evaluate these dynamics, the prospective real-world study followed 75 patients initiating dapagliflozin, of whom 65 individuals completed the six-month follow-up period and were included in the final analysis. Blood pressure evaluations were conducted at baseline and repeated after six months of dapagliflozin therapy.

The study protocol assessed hemodynamic changes across multiple modalities, specifically incorporating office blood pressure, central aortic measurements, and 24-hour ambulatory monitoring. Researchers calculated absolute and relative blood pressure changes from baseline to the six-month assessment, evaluating associations between initial readings and subsequent changes through correlation and linear regression analyses. Multivariable ANCOVA models were constructed to adjust for baseline blood pressure, patient age, sex, diabetes status, renal function, and medication treatment modifications. In these multivariable models, baseline blood pressure remained the strongest predictor of follow-up blood pressure values, reinforcing the baseline-dependent pattern observed across clinical evaluations.

Hemodynamic safety was evaluated using predefined low blood pressure thresholds, and investigators observed no increase in the prevalence of measurements falling below these safety limits during follow-up. These observational findings offer clinical reassurance regarding the blood pressure profile following dapagliflozin initiation in real-world practice, aligning with the hemodynamic safety reported in randomized clinical trials. However, the authors noted that because the study used a single-arm observational design without a protocolized background therapy regimen, blood pressure changes should not be attributed exclusively to dapagliflozin, as the observed pattern may reflect the combined influence of baseline blood pressure, regression-to-the-mean, overall clinical stabilization, measurement variability, and non-protocolized medication adjustments.

Subject of Research: Blood pressure response to dapagliflozin in heart failure with reduced ejection fraction

Article Title: Baseline-dependent blood pressure response to dapagliflozin in real-world HFrEF: insights from office, ambulatory, and central measurements

Article References: Wierzowiecka, M., Wysocki, A., Begier-Krasińska, B., Spasenenko, I., Marcinkowska, J., & Niklas, A. (2026). Baseline-dependent blood pressure response to dapagliflozin in real-world HFrEF: insights from office, ambulatory, and central measurements. BMC Cardiovascular Disorders. https://doi.org/10.1186/s12872-026-06961-9

Image Credits: AI Generated

DOI: 10.1186/s12872-026-06961-9

Keywords: dapagliflozin, heart failure, reduced ejection fraction, blood pressure, ambulatory blood pressure, central blood pressure, hemodynamic safety, observational study, Baseline-dependent, blood, pressure, response

News Source: Ophelia Keating. (November 8, 2026). Heart Failure Study Shows Baseline Dependent Blood Pressure Changes With Dapagliflozin. Scienmag.

Tags: ambulatory blood pressureBaseline-dependentbloodblood pressurecentral blood pressuredapagliflozinheart failurehemodynamic safetyObservational studypressurereduced ejection fractionresponse
Share12Tweet7Share2ShareShareShare1

Related Posts

Cervical Dumbbell Tumor Anatomy and Artery Encasement Predict Incomplete Surgical Resection

Cervical Dumbbell Tumor Anatomy and Artery Encasement Predict Incomplete Surgical Resection

November 17, 2026
Review Links Acid-Sensing Ion Channels to Chronic Pain and Psychiatric Comorbidities

Review Links Acid-Sensing Ion Channels to Chronic Pain and Psychiatric Comorbidities

November 17, 2026

First-Trimester Immune-Inflammatory Indices Associate With Miscarriage in Recurrent Pregnancy Loss

November 17, 2026

Hyperbolic Graph Model Accurately Predicts Adverse Drug Reactions in Pharmacovigilance

November 17, 2026

POPULAR NEWS

  • Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    29 shares
    Share 12 Tweet 7
  • Quality Improvement Project Raises Pre-Antibiotic Microbiological Analysis Rate to 79.2 Percent

    29 shares
    Share 12 Tweet 7
  • LLM-Driven Social Simulations Face Significant Epistemic Validity Challenges

    29 shares
    Share 12 Tweet 7
  • Veterinary Brucellosis Testing Requires Validated Decision Rules Across Animal Populations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cervical Dumbbell Tumor Anatomy and Artery Encasement Predict Incomplete Surgical Resection

Review Links Acid-Sensing Ion Channels to Chronic Pain and Psychiatric Comorbidities

First-Trimester Immune-Inflammatory Indices Associate With Miscarriage in Recurrent Pregnancy Loss

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.